| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Small round cell sarcoma is a diagnostic category that encompasses a variety of sarcoma entities which share predominantly small round-shaped tumor cytology. Most small round cell sarcomas are readily classifiable; however, approximately 5-10% of tumors defy definitive classification based on the present nosologic scheme. These unclassifiable small round cell sarcomas are hypothesized to consist of multiple distinct entities, each of which should be recognized and treated by specific strategy. In this study, we first identified a number of unclassifiable small round cell sarcomas in our archive, and then analyzed them by using clinicopathological and molecular methods including next generation sequencing. We identified a relatively large series of novel entities such as CIC-rearranged sarcoma and SMARCA4-deficient thoracic sarcoma, and characterized them in detail to better understand these under-recognized malignancies.
|
